(Q26850892)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Targeting triple-negative breast cancer: optimising therapeutic outcomes (English)

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

triple-negative breast cancer

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

K Gelmon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

R Dent

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

K Laing

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

D McLeod

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

S Verma

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

1 reference

19 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

23

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

9

2 references

PubMed

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

2223-2234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

The molecular portraits of breast tumors are conserved across microarray platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Molecular stratification of triple-negative breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Deconstructing the molecular portraits of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Hallmarks of 'BRCAness' in sporadic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Basal-like subtype and BRCA1 dysfunction in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

BRCA1 dysfunction in sporadic basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Epidemiology of basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Subtypes of breast cancer show preferential site of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Homologous recombinational repair of DNA ensures mammalian chromosome stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Genome maintenance mechanisms for preventing cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Cisplatin versus carboplatin in NSCLC: is there one "best" answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Avastin hearing leads to more uncertainty over drug's future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Triple negative breast cancer: unmet medical needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Platinum-based chemotherapy in triple-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Characteristics of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

PARP inhibitors for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

7 January 2021

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

1 reference

7 January 2021

Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

7 January 2021

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS067

7 January 2021

Identifiers

DOI

10.1093/ANNONC/MDS067

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22517820%20AND%20SRC:MED&resulttype=core&format=json